Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy

  • Authors:
    • Anna Maria Cattelan
    • Maria Luisa Calabrò
    • Anita De Rossi
    • Savina Maria Luciana Aversa
    • Massimo Barbierato
    • Marco Trevenzoli
    • Paola Gasperini
    • Marisa Zanchetta
    • Paolo Cadrobbi
    • Silvio Monfardini
    • Luigi Chieco-Bianchi
  • View Affiliations

  • Published online on: September 1, 2005     https://doi.org/10.3892/ijo.27.3.779
  • Pages: 779-785
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The long-term impact of highly active antiretroviral therapy (HAART) in AIDS patients with Kaposi's sarcoma (KS) was evaluated in 22 consecutive, HAART-naïve KS patients attending a single Italian referral centre for HIV/AIDS. Clinical, virologic and immunologic responses to HAART were assessed at baseline and every three months during the follow-up. Peripheral blood mononuclear cell (PBMC)-associated human herpesvirus 8 (HHV-8) load was also evaluated by real-time PCR in 13 patients with durable clinical KS complete response (CR). In a median follow-up of 40 months (range 17-78), the KS overall clinical response rate was 91%: 18 complete and 2 partial responses were achieved, and two patients experienced disease progression. CR persisted in all 18 patients, including the 5 poor-risk KS patients in whom CR lasted for >60 months, and was significantly linked to an increase in CD4+ cell counts and a drop in HIV-1-RNA copies. Compared to baseline levels, a decrease in PBMC HHV-8 load was observed at CR, and a significant further reduction was found at the end of follow-up. In this monocentric study, AIDS-KS patients treated with HAART showed high clinical response rate. Patients with CR showed a prolonged remission, lasting more than 5 years in a group of poor-risk patients, and a persistent reduction in circulating HHV-8-infected cells. These findings highlight that HAART deeply modifies the natural history of this tumour in AIDS patients, and that this long-lasting approach may be considered a first-line treatment for the majority of HIV-1-infected patients developing KS.

Related Articles

Journal Cover

September 2005
Volume 27 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cattelan AM, Calabrò ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, Gasperini P, Zanchetta M, Cadrobbi P, Monfardini S, Monfardini S, et al: Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol 27: 779-785, 2005
APA
Cattelan, A.M., Calabrò, M.L., De Rossi, A., Aversa, S.M., Barbierato, M., Trevenzoli, M. ... Chieco-Bianchi, L. (2005). Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. International Journal of Oncology, 27, 779-785. https://doi.org/10.3892/ijo.27.3.779
MLA
Cattelan, A. M., Calabrò, M. L., De Rossi, A., Aversa, S. M., Barbierato, M., Trevenzoli, M., Gasperini, P., Zanchetta, M., Cadrobbi, P., Monfardini, S., Chieco-Bianchi, L."Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy". International Journal of Oncology 27.3 (2005): 779-785.
Chicago
Cattelan, A. M., Calabrò, M. L., De Rossi, A., Aversa, S. M., Barbierato, M., Trevenzoli, M., Gasperini, P., Zanchetta, M., Cadrobbi, P., Monfardini, S., Chieco-Bianchi, L."Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy". International Journal of Oncology 27, no. 3 (2005): 779-785. https://doi.org/10.3892/ijo.27.3.779